Moderna, Inc. (BVMF:M1RN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 97.82B +68.5% |
| Revenue (ttm) | 11.61B -30.0% |
| Net Income | -16.66B |
| EPS | -42.59 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,376 |
| Open | 12.43 |
| Previous Close | 12.46 |
| Day's Range | 11.80 - 12.43 |
| 52-Week Range | 6.02 - 15.53 |
| Beta | 1.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy focused on global expansion, product diversification, and disciplined cost control, targeting up to 10% revenue growth and cash flow breakeven by 2028. Key pipeline assets, including intismeran and a norovirus vaccine, are expected to drive substantial future growth, with new launches and market share gains in both the U.S. and Europe.
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1] The INTERCEPT-Lynch trial is part of a scientific collaboration between the Universi...
Moderna price target raised to $34 from $32 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $34 from $32 and keeps an Underperform rating on the shares after having hosted Moderna’s CEO for a group lunch.
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”
eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna custome...
Moderna to Present at Upcoming Conference in June 2026
CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Goldman Sachs 47th Annual Global Healthca...
Moderna Transcript: Study update
Intismeran, an individualized mRNA neoantigen therapy, showed a 49% reduction in recurrence risk and strong safety in phase II melanoma trials. Mechanistic data confirmed robust, durable T cell responses linked to efficacy, supporting expansion to other cancers and large-scale manufacturing.
Moderna Press release: Study update
Moderna issued a press release on June 1, 2026, disclosing material business information to investors.
Moderna Slides: Study update
Moderna has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Moderna, Merck to present 5-year data for intismeran autogene
Moderna (MRNA) and Merck (MRK), known as MSD outside of the United States and Canada, announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA...
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurr...
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine
Moderna said on Monday it has partnered with the Coalition for Epidemic Preparedness Innovations to develop a potential vaccine against Bundibugyo ebolavirus, the strain linked to the ongoing Ebola...
Moderna expands pact with CEPI to advance potential vaccine against BDBV
Moderna (MRNA) announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations, or CEPI, to advance the development of a potential vaccine against Bundibugyo ebolavirus, o...
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswir...
Moderna Transcript: Bernstein 42nd Annual Strategic Decisions Conference
The business has evolved from research to a global commercial platform, with a diversified vaccine and oncology pipeline, robust cost management, and deep integration of AI across operations. AI and quantum computing are expected to accelerate drug discovery and operational efficiency, while new competitors validate the vaccine market.
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Th...
US FDA to hold expert committee meeting to review Moderna's flu vaccine
The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot.
FDA to hold advisory hearing to debate Moderna’s flu vaccine, Bloomberg reports
Moderna’s (MRNA) experimental mRNA-based flu vaccine will be reviewed by an FDA advisory panel on June 18 ahead of an August 5 approval decision, signaling a possible return to greater…
Moderna Transcript: RBC Capital Markets Global Healthcare Conference 2026
Cost reductions and strong sales in 2025 set the stage for 2026 growth, led by ex-U.S. partnerships and new vaccine launches. Key clinical milestones include durable melanoma data and upcoming regulatory decisions for flu and combo vaccines. Legal risks from IP disputes are considered low-probability.
Moderna Recognized by TIME as One of the World's Most Impactful Companies
CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.
Moderna Transcript: Bank of America Global Healthcare Conference 2026
Revenue growth of up to 10% is expected in 2026, driven by mRESVIA and strategic partnerships, with breakeven targeted for 2028. Regulatory milestones, including a key flu vaccine PDUFA date and EU market expansion in 2027, support growth, while oncology and pandemic preparedness programs advance.
Moderna's AI Could Get a Hantavirus Vaccine Here Faster
Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.
Hantavirus outbreak: these 3 stocks are poised to rip higher
The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed ...
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.
Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.
Here's how much Moderna's stock has rallied off renewed focus on hantavirus research
The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.